Analyst Conference Summaries

Biotechnology Investor Aids

Merrimack Pharmaceuticals
MACK

"Cancer is anarchy: the loss of governance alters a broad range of connected cellular processes that dynamically interact with the microenvironment." — Merrimack R&D presentation, 2016

conference date: March 1, 2017 @ 5:30 AM Pacific Time

FDA Approves Merrimack Onivyde for Pancreatic Cancer [October 22, 2015]

Analyst Conference Notes by William P. Meyers
2016
05/02/2016
08/04/2016
11/09/2016
03/01/2017 
2015
05/07/2015
08/10/2015
11/09/2015
02/25/2016
2014
not available
08/11/2014
11/10/2014
02/26/2015

Merrimack Phramaceuticals (MACK) is a biotechnology company focused on cancer therapies.

Merrimack Phramaceuticals web site
Merrimack Phramaceuticals investor relations page


 

Search

More Analyst Conference Pages:

 AGEN
 AGIO
 ALNY
 ALXN
 AMAT
 AMD
 AMGN
 BIIB
 BIND
 CLDX
 CELG
 EPZM
 GILD
 GLYC
 HNSN
 INO
 INTC
 ISRG
 JUNO
 MACK
 MCHP
 MDVN
 MYL.
 NVDA
 OPXA
 PLX
 REGN
 SGEN
 XLNX
 XLRN

 

Disclaimer: Our analyst summaries may include both our condensations of statements made by company representatives and our own analysis. They are not covered by any warranty. We cannot guarantee anything said by company representatives is true. We try not to make errors, but it is possible. Before making or terminating an investment you should always verify any factual basis of your decision.

Copyright 2013 William P. Meyers